Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.33 |
| ▸ | RAB9A | P51151 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8931046 | 0.80 | HSP90AA1 (0.64) | HSP90AA1MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL931818 | 0.76 | HSP90AA1 (0.43) | HSP90AA1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL4941528 | 0.76 | HSP90AA1 (0.61) | HSP90AA1 | |
| SCHEMBL1305610 | 0.76 | HTR1A (0.33) | ALDH1A1HTR1AHTR2AHPGD | |
| SCHEMBL4936858 | 0.74 | HSP90AA1 (0.60) | HSP90AA1MAPTKDM4EKMT2AGAA | |
| SCHEMBL930881 | 0.74 | HSP90AA1 (0.50) | HSP90AA1MAPTKDM4EKMT2AGAA | |
| SCHEMBL14342548 | 0.73 | HTR1A (0.31) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL8931041 | 0.71 | HSP90AA1 (0.40) | HSP90AA1RAB9AMAPTKDM4EMEN1 | |
| SCHEMBL4943310 | 0.71 | HSP90AA1 (0.64) | HSP90AA1ALDH1A1HPGD | |
| SCHEMBL4940434 | 0.68 | ACHE (0.41) | HSP90AA1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298748-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2298748-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9090569-B2 | Triazone compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| WO-2007139960-A2 | COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139952-A2 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS WITH HSP90 MODULATING ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885NPC1 554/4885RAB9A 3565/4885 |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885NPC1 660/4885RAB9A 2109/4885 |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | HSP90AB1, HSP90B1, CDC37 | HSP90AA1 4/4885NPC1 1592/4885RAB9A 3579/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885NPC1 1322/4885RAB9A 1686/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885NPC1 1229/4885RAB9A 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.